Kehinde Junaid
Overview
Explore the profile of Kehinde Junaid including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
122
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Harwood R, Goldberg S, Brand A, der Wardt V, Booth V, Di Lorito C, et al.
BMJ
. 2023 Aug;
382:e074787.
PMID: 37643788
Objective: To determine the effectiveness of an exercise and functional activity therapy intervention in adults with early dementia or mild cognitive impairment compared with usual care. Design: Randomised controlled trial....
2.
Hosseini A, Brown T, Mannino L, Gran B, Junaid K, Mukaetova-Ladinska E
J Alzheimers Dis
. 2022 Apr;
87(2):771-780.
PMID: 35404281
Background: The differentiation of a preclinical or prodromal Alzheimer's disease (AD) is challenging particularly in patients with early onset Alzheimer's or related dementias (EOARD). We report our experience on diagnostic...
3.
Crowther G, Chinnasamy M, Bradbury S, Shaw L, Ormerod S, Wilkinson A, et al.
Int J Geriatr Psychiatry
. 2021 Apr;
36(9):1415-1422.
PMID: 33860554
Introduction: The number of people over the age of 65 attending Emergency Departments (ED) in the United Kingdom (UK) is increasing. Those who attend with a mental health related problem...
4.
Femminella G, Livingston N, Raza S, van der Doef T, Frangou E, Love S, et al.
Alzheimers Res Ther
. 2021 Feb;
13(1):47.
PMID: 33597002
Background: Type 2 diabetes is a risk factor for Alzheimer's disease (AD), and AD brain shows impaired insulin signalling. The role of peripheral insulin resistance on AD aetiopathogenesis in non-diabetic...
5.
Femminella G, Frangou E, Love S, Busza G, Holmes C, Ritchie C, et al.
Trials
. 2020 Jul;
21(1):660.
PMID: 32684162
An amendment to this paper has been published and can be accessed via the original article.
6.
Femminella G, Frangou E, Love S, Busza G, Holmes C, Ritchie C, et al.
Trials
. 2019 Apr;
20(1):191.
PMID: 30944040
Background: Liraglutide is a glucagon-like peptide-1 (GLP-1) analogue currently approved for type 2 diabetes and obesity. Preclinical evidence in transgenic models of Alzheimer's disease suggests that liraglutide exerts neuroprotective effects...